Its development has been supported by the Horizon 2020 funding program of the EU. Altogether a total of nine partners have contributed to the development of the device. SniffPhone is held in front of the mouth and the patient exhales to supply a breath sample to the sensor. The device measures volatile organic compounds contained in the sample using highly sensitive nanotechnology chemical sensors. The measurement results are sent via Bluetooth using a smartphone to a dedicated cloud platform where the data can be accessed for analysis and diagnosis by medical staff.
Electronic diagnosisThis new cancer screening procedure has many advantages over traditional methods. The hand-held device is user-friendly and provides a simple, fast and cost-effective method to detect bio-markers produced by many types of gastro-intestinal conditions. The SniffPhone prototypes have been proven in a series of clinical trials and the team are now looking for financial support to fund production.
The Finnish research centre VTT are one of the project partners; their primary job was to implement the communication links and they are also developing analysis tools to identify high-risk patients for certain medical conditions to assist diagnosis.